Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.35 |
| ▸ | PDE4A | P27815 | 9/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274953 | 1.00 | PTGDR2 (0.36) | PTGDR2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL274398 | 0.99 | PDE4D (0.36) | PTGDR2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL279473 | 0.99 | PDE4D (0.36) | PTGDR2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL276376 | 0.90 | SYK (0.39) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL279161 | 0.90 | SYK (0.39) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL275957 | 0.89 | FPR2 (0.34) | — | |
| SCHEMBL278963 | 0.89 | FPR2 (0.34) | — | |
| SCHEMBL279490 | 0.86 | HPGD (0.36) | PTGDR2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL274631 | 0.86 | HPGD (0.36) | PTGDR2PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL276159 | 0.86 | PDE4D (0.35) | PDE4DPDE4APDE4BPDE4CMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134001-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156610-A1 | Spiroindolinone Derivatives | SDHA, AR, XPOT | PTGDR2 996/4885PDE4D 2759/4885PDE4A 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.